margin of improving outcomes for patients with SCLC using surgery is narrow, and outcomes are dependent on multidisciplinary decision making and treatment. Until other studies demonstrate flexibility, surgeons must strive for guideline concordance. This is the way.

References

1. NCCN Clinical Practice Guidelines in Oncology: small cell lung cancer version 1. Available at: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed November 17, 2020.
2. Yang C-F, Chan DY, Shah S, Yerokun B, Wang XF, D'Amico TA, et al. Long-term survival after surgery compared with concurrent chemoradiation for node-negative small cell lung cancer. *Ann Surg*. 2018;268:1105-12.
3. Yang C-F, Chan DY, Speicher PJ, Gulack BC, Tong BC, Hartwig MG, et al. Surgery vs optimal medical management for N1 small cell lung cancer. *Ann Thorac Surg*. 2017;103:1767-72.
4. Yang C-F, Chan DY, Speicher PJ, Gulack BC, Wang X, Hartwig MG, et al. The role of adjuvant therapy in a population-based cohort of patients with early stage small cell lung cancer. *J Clin Oncol*. 2016;34:1057-64.
5. Pietanza MC. Using a population-based analysis to determine the management and treatment of early-stage small-cell lung cancer. *J Clin Oncol*. 2016;34:1027-9.
6. Raman V, Jawitz O, Yang CF, Voigt S, D'Amico TA, Harpole DH, et al. The effect of extent of resection on outcomes in patients with limited stage small cell lung cancer. *J Thorac Cardiovasc Surg*. March 22, 2020 [Epub ahead of print].
7. Zhou N, Bott M, Park BJ, Vallières E, Wilshire CL, Yasufuku K, et al. Predictors of survival following surgical resection of limited stage small cell lung cancer. *J Thorac Cardiovasc Surg*. 2021;161:760-71.e2.

See Article page 760.

Commentary: Survival after small cell lung cancer resection: Small opportunity?

Mark Onaitis, MD

Opportunities to enhance survival of patients with non-small cell lung cancer are common for thoracic surgeons, and algorithms for adjuvant therapy are clear. Multiple studies have demonstrated long-term survival improvement with adjuvant chemotherapy for node-positive patients. However, less is known regarding the much less common circumstance of complete resection of limited-stage small cell lung cancer. A National Cancer Database study recently demonstrated that adjuvant chemotherapy improves survival in resected small cell lung cancer patients.¹ The current study helps shed some light on the topic because it demonstrates, in an analysis of patients resected at several major centers over 33 years, that adjuvant chemotherapy

Mark Onaitis, MD

CENTRAL MESSAGE

A strategy of resection of limited-stage small cell carcinoma with anatomic resection followed by adjuvant chemotherapy may improve survival over resection followed by no chemotherapy.

improves survival after surgical resection regardless of pathologic lymph node status.²

Strengths of the article include its multi-institutional nature, the relatively large sample size for a rare clinical situation, and the long time period covered. The premise also makes sense: Small cell lung cancer usually manifests with multiple distant metastases and these patients often have excellent initial responses to systemic chemotherapy and immunotherapy.³ It thus follows that systemic chemotherapy would help patients with limited-stage disease and presumed micrometastases. However, we must take pause in interpretation of the current study. First, confounding is a large issue in a retrospective study like this. Perhaps the patients who received chemotherapy were healthier than the cohort that did not receive

From the Division of Cardiothoracic Surgery, University of California, San Diego, La Jolla, Calif.

Disclosures: The author reported no conflicts of interest.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

Received for publication Nov 15, 2020; revisions received Nov 15, 2020; accepted for publication Nov 17, 2020; available ahead of print Nov 24, 2020.

Address for reprints: Mark Onaitis, MD, Division of Cardiothoracic Surgery, University of California, San Diego, 9300 Campus Point Dr, Mailcode 7892, La Jolla, CA 92037 (E-mail: monaitis@ucsd.edu).

J Thorac Cardiovasc Surg 2021;161:773-4

0022-5223/\$36.00

Copyright © 2021 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery

<https://doi.org/10.1016/j.jtcvs.2020.11.069>

therapy. Alternatively, perhaps some of the patients who were not known to have received chemotherapy actually did receive chemotherapy at centers that are not as high quality as those included in the current study. Also, because of the long time frame of the study, positron-emission tomography was only performed on 17% of the study population making accurate staging problematic. Next, a substantial percentage of patients in this study had tumors that were node positive or greater than T2. Presumably, these patients had resection of lesions without initial biopsy with surprise histology and nodal upstaging were found on pathologic analysis. In the modern era, preoperative histologic analysis of mediastinal and hilar lymph nodes for larger and central tumors would allow for purer stages for analysis.

Aside from adjuvant therapy, the natural history of nonhilar small cell tumors is unclear. We generally accept that non-small cell carcinoma spreads centripetally to segmental, hilar, and then mediastinal nodes. Anatomic resection with hilar and mediastinal lymph node dissection is effective because all disease is resected.⁴ Whether or not small cell lung cancer is similar in pattern of spread is less clear. Although hematologic spread seems more common, the current study demonstrates survival improvement of lobectomy

over sublobar resection. Although confounding may again be an issue, this is an important finding for surgeons. Complete resection of all disease may be possible in some patients with anatomic resection.

As imaging and the ability to use navigational bronchoscopy and liquid biopsy to diagnose patients continue to improve, surgeons will see more limited-stage small cell lung cancer that is resectable. Clearly, anatomic resection with adjuvant chemotherapy provides reasonable survival and should be the procedure of choice at present. As the number of these patients increases, opportunities to analyze the condition in more granular ways will exist.

References

1. Yang CF, Chan DY, Speicher PJ, Gulack BC, Wang X, Hartwig MG, et al. Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer. *J Clin Oncol*. 2016;34:1057-64.
2. Zhou N, Bott M, Park BJ, Vallieres E, Wilshire CL, Yasufuku K, et al. Predictors of survival following surgical resection of limited stage small cell lung cancer. *J Thorac Cardiovasc Surg*. 2021;161:760-71.e2.
3. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. *N Engl J Med*. 2018;379:2220-9.
4. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung cancer study group. *Ann Thorac Surg*. 1995;60:615-22.

See Article page 760.

Commentary: Find, resect, and treat: The evolving early-stage small cell lung cancer story

Scott J. Swanson, MD

The paper by Zhou and colleagues¹ in this issue of the *Journal* analyzes a cohort of 169 patients who had surgery for limited-stage small cell lung cancer over a 30-year period at 5 excellent institutions in North America. Their

Scott J. Swanson, MD

CENTRAL MESSAGE

Patients with early-stage small cell lung cancer should be offered surgical resection followed by systemic chemotherapy.

From the Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass.

Disclosures: The author reported no conflicts of interest.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

Received for publication Nov 9, 2020; revisions received Nov 9, 2020; accepted for publication Nov 11, 2020; available ahead of print Nov 21, 2020.

Address for reprints: Scott J. Swanson, MD, Division of Thoracic Surgery, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115 (E-mail: sjswanson@bwh.harvard.edu).

J Thorac Cardiovasc Surg 2021;161:774-5
0022-5223/\$36.00

Copyright © 2020 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery
<https://doi.org/10.1016/j.jtcvs.2020.11.033>

surgical results were superb, and the careful analysis demonstrated a survival benefit for adjuvant chemotherapy